Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort

Anwaar Saeed, Robin Park, Harsh B. Pathak, Ayah N. Al-Bzour, Junqiang Dai, Milind A. Phadnis, Raed Moh’d Taiseer Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun,

Nature Communications · 2024 · 36 citations · 61 references

DOIFull text

Open access

References

61